Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group.
about
Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patientsInterventions for preventing oral candidiasis for patients with cancer receiving treatmentSystematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipientsAmphotericin B vs fluconazole for controlling fungal infections in neutropenic cancer patients.Fungal infection-related mortality versus total mortality as an outcome in trials of antifungal agents.Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study.Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data.Aspergillus infections in transplant recipients.Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant.Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?Evidence-based guidelines for empirical therapy of neutropenic fever in Korea.Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients.Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysPrimary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia.Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies.Minimizing the risk of recurrent or progressive invasive mold infections during stem cell transplantation or further intensive chemotherapy.Safety and Efficacy of Intermittent Intravenous Administration of High-Dose Micafungin.Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.Weekly liposomal amphotericin B as secondary prophylaxis for invasive fungal infections in patients with hematological malignancies.Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts.Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients.Therapeutic strategies for invasive fungal infections in neonatal and pediatric patients: an update.The impact of oral herpes simplex virus infection and candidiasis on chemotherapy-induced oral mucositis among patients with hematological malignancies.Cost-effectiveness analysis of antifungal treatment for patients on chemotherapy.Antifungal chemoprophylaxis after blood and marrow transplantation.Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice.Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation.Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients.Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation.Cost-effectiveness analysis of voriconazole, fluconazole, and amphotericin B for invasive fungal infections following allogeneic hematopoietic stem cell transplantation in Mexico
P2860
Q24193785-5149F581-0E73-4A79-92CF-56779E41B31DQ24243005-FD558617-58D1-407C-8F08-B99E1BB7329DQ28083874-0274BB16-3DBD-413F-AA2C-DAE20FAE8643Q30887333-CBD89248-F435-4392-8B7E-F096B7A5247FQ33253851-64138C85-51DD-47FC-AA2C-A537151AD27CQ33289645-3336D4DF-C848-4CAA-9605-F2D1BEE37640Q33559503-20CE824F-BF9E-4E6D-A654-372FFF4057DCQ33719294-952A6BC7-A136-4575-988E-B6C224447E60Q33722115-4E4C82E3-3D3F-49B8-A5D1-B3C37FFC3F66Q34490092-D404AB74-5B1F-4910-9960-E569C02E446AQ35033597-D9CE8E0F-6E02-490F-BC4C-C01E869A82FFQ35833407-7ECC8B3F-BE5F-46C6-B80B-ADE5C17F9288Q35949528-74B47927-1ED2-49D0-B634-83A2AB3E5B11Q36406975-1A791078-609C-4845-AAAE-8EC42E89B0A5Q36714507-1EE7DB98-A379-444D-B74A-319D146EABB4Q36867435-BF58E717-DAD0-47B0-8829-7B45AB4B2F55Q37220447-4B48205A-35DC-4AD9-9032-1181D86F8DE8Q37344532-E16DC90D-CCBD-49FF-866E-D6459D241538Q37442798-AE19B195-78B7-4A73-B69D-81A5D5EA17AEQ37621550-B779DDFD-DD56-480C-946A-0765099F6972Q38178526-703A20A9-31DB-41DB-9699-E80333CC1043Q38353420-E7640B36-2FBB-42C9-A858-7D8B57ADEA4AQ40337532-729D91F3-76F4-42BA-9D5B-78B413FE8235Q40487519-53C5F964-0A4D-42AF-826C-14F41E35393BQ40643653-4F7C0EAA-CD73-4E25-952C-58EB66D7944DQ44750606-D78D7D0A-ED04-47D2-BDEF-21D719843B1CQ53626853-92786828-7591-418E-A393-B5D589E671EFQ53652426-EA0B25D1-0737-4A35-BC36-A199E289DD58Q53664706-00BF9D0D-399F-4113-9692-F679170DAFA6Q58761662-32F0BFBD-DF98-4584-A018-BC61B49915FB
P2860
Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group.
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Fluconazole vs low-dose amphot ...... rican Marrow Transplant Group.
@ast
Fluconazole vs low-dose amphot ...... rican Marrow Transplant Group.
@en
type
label
Fluconazole vs low-dose amphot ...... rican Marrow Transplant Group.
@ast
Fluconazole vs low-dose amphot ...... rican Marrow Transplant Group.
@en
prefLabel
Fluconazole vs low-dose amphot ...... rican Marrow Transplant Group.
@ast
Fluconazole vs low-dose amphot ...... rican Marrow Transplant Group.
@en
P2093
P2860
P356
P1476
Fluconazole vs low-dose amphot ...... rican Marrow Transplant Group.
@en
P2093
C O Freytes
F LeMaistre
P2860
P2888
P304
P356
10.1038/SJ.BMT.1702233
P407
P577
2000-04-01T00:00:00Z
P5875
P6179
1004430684